Beyond market averages, investors seeking exceptional growth focus on the art of stock selection. The right picks can significantly contribute to the expansion of your wealth.
As of close of business last night, Procept BioRobotics Corp’s stock clocked out at $40.71, down -2.12% from its previous closing price of $41.59. In other words, the price has decreased by -$2.12 from its previous closing price. On the day, 0.8 million shares were traded. PRCT stock price reached its highest trading level at $42.04 during the session, while it also had its lowest trading level at $40.6.
Ratios:
To gain a deeper understanding of PRCT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 7.86 and its Current Ratio is at 9.20. In the meantime, Its Debt-to-Equity ratio is 0.21 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Stephens on July 09, 2025, initiated with a Overweight rating and assigned the stock a target price of $70.
On December 02, 2024, Morgan Stanley started tracking the stock assigning a Overweight rating and target price of $105.Morgan Stanley initiated its Overweight rating on December 02, 2024, with a $105 target price.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 13 ’25 when MOLL FREDERIC H bought 20,000 shares for $39.26 per share. The transaction valued at 785,138 led to the insider holds 863,159 shares of the business.
Desai Antal Rohit sold 25,000 shares of PRCT for $1,597,711 on Jun 10 ’25. The Director now owns 64,363 shares after completing the transaction at $63.91 per share. On Jun 11 ’25, another insider, Desai Antal Rohit, who serves as the Director of the company, sold 25,000 shares for $63.38 each. As a result, the insider received 1,584,525 and left with 39,363 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PRCT now has a Market Capitalization of 2264937472 and an Enterprise Value of 2041589120. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.24 while its Price-to-Book (P/B) ratio in mrq is 5.86. Its current Enterprise Value per Revenue stands at 7.425 whereas that against EBITDA is -23.762.
Stock Price History:
The Beta on a monthly basis for PRCT is 1.03, which has changed by -0.3737405 over the last 52 weeks, in comparison to a change of 0.15222645 over the same period for the S&P500. Over the past 52 weeks, PRCT has reached a high of $103.81, while it has fallen to a 52-week low of $37.12. The 50-Day Moving Average of the stock is -25.28%, while the 200-Day Moving Average is calculated to be -39.17%.
Shares Statistics:
It appears that PRCT traded 1.07M shares on average per day over the past three months and 1760430 shares per day over the past ten days. A total of 55.58M shares are outstanding, with a floating share count of 52.86M. Insiders hold about 4.93% of the company’s shares, while institutions hold 96.28% stake in the company. Shares short for PRCT as of 1753920000 were 7119045 with a Short Ratio of 6.63, compared to 1751241600 on 6808235. Therefore, it implies a Short% of Shares Outstanding of 7119045 and a Short% of Float of 15.160000000000002.
Earnings Estimates
The stock of Procept BioRobotics Corp (PRCT) is currently drawing attention from 9.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is -$0.26, with high estimates of -$0.23 and low estimates of -$0.28.
Analysts are recommending an EPS of between -$1.45 and -$1.51 for the fiscal current year, implying an average EPS of -$1.49. EPS for the following year is -$0.94, with 9.0 analysts recommending between -$0.41 and -$1.3.
Revenue Estimates
In the current quarter, 11 analysts expect revenue to total $80.78M. It ranges from a high estimate of $82.05M to a low estimate of $79.63M. As of the current estimate, Procept BioRobotics Corp’s year-ago sales were $58.37MFor the next quarter, 11 analysts are estimating revenue of $96.43M. There is a high estimate of $97.37M for the next quarter, whereas the lowest estimate is $95.37M.
A total of 12 analysts have provided revenue estimates for PRCT’s current fiscal year. The highest revenue estimate was $337.31M, while the lowest revenue estimate was $325.35M, resulting in an average revenue estimate of $326.53M. In the same quarter a year ago, actual revenue was $224.5MBased on 12 analysts’ estimates, the company’s revenue will be $426.85M in the next fiscal year. The high estimate is $433.5M and the low estimate is $416.1M.
